Treatment of AIDS Vacuolar Myelopathy With Methionine

This study has been completed.
Sponsor:
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier:
NCT00032695
First received: March 28, 2002
Last updated: May 12, 2006
Last verified: November 2005
  Purpose

The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.


Condition Intervention Phase
Myelopathy
AIDS-Myelopathy
AIDS Vacuolar Myelopathy
Drug: methionine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Estimated Enrollment: 56
Detailed Description:

Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Between 18 and 80 years of age

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032695

Locations
United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
Investigators
Principal Investigator: Alessandro Di Rocco, MD
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00032695     History of Changes
Other Study ID Numbers: R01NS35745
Study First Received: March 28, 2002
Last Updated: May 12, 2006
Health Authority: United States: Federal Government

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
myelopathy
AIDS-myelopathy
AIDS vacuolar myelopathy
methionine

Additional relevant MeSH terms:
Bone Marrow Diseases
Hematologic Diseases

ClinicalTrials.gov processed this record on September 30, 2014